Study of Tranexamic Acid During Air Medical Prehospital Transport Trial (STAAMP Trial) - TACR
Abstract
Multi-center, prospective, randomized, blinded, controlled interventional trial focusing on patients with concern for bleeding who are transported via medical transport to definitive care. The primary hypothesis is that the prehospital infusion of tranexamic acid in patients at risk for bleeding will reduce the incidence of 30-day mortality. The secondary hypotheses include that prehospital tranexamic acid will reduce the incidence of hyperfibrinolysis, acute lung injury, multiple organ failure, nosocomial infection, mortality, early seizures, pulmonary embolism and early resuscitation needs, reduce or prevent the early coagulopathy as demonstrated by improving presenting INR and rapid thromboelastography parameters, reduce the early inflammatory response, plasmin levels, leukocyte, platelet and complement activation, and determine the optimal dosing of tranexamic acid post-injury.
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 01, 2020
- Accession Number
- AD1125529
Entities
People
- Jason Lee Sperry
Organizations
- University of Pittsburgh